Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab perioperative therapy for resectable locoregionally advanced head and neck squamous cell carcinoma
2022-500254-41-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Event-free Survival. Planned start Dec 2018; status: authorised.
02
Drugs
pembrolizumabcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-500254-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500254-41-00.